Taho Pharmaceuticals Ltd. (TPEX:6467)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
127.00
+4.50 (3.67%)
At close: May 29, 2026
Market Cap6.53B +117.5%
Revenue (ttm)7.78M
Net Income-165.97M
EPS-3.37
Shares Out 51.39M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume219,374
Open123.00
Previous Close122.50
Day's Range123.00 - 129.50
52-Week Range45.60 - 208.50
Beta-34.06
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About Taho Pharmaceuticals

Taho Pharmaceuticals Ltd., a pharmaceutical company, develops products using transdermal and transmucosal systems in Taiwan. Its pipeline includes TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting; and TAH3311 Apixaban oral film and TAH3341 Apixaban oral extend release films for patients with Dysphagia. The company also develops TAH2211 Buprenorphine/Naloxone sublingual film and TAH2231 Naloxone Buccal film for Opioid overdose; TAH9922 Atomoxetine oral liquid an... [Read more]

Industry Pharmaceutical Preparations
Founded 2010
Employees 27
Stock Exchange Taipei Exchange
Ticker Symbol 6467
Full Company Profile

Financial Performance

Financial Statements